Stock performances of European biotech companies: status at the end of Q3 2019

The ranking of the 9-month 2019 stock performance is shown below. 42% of the field was in positive territory at the end of September, and 58% in negative territory.
As one can see, the top tail of the vertical waterfall plot is fully red (UK/IE cluster). Consistently with previous comments, there is a lot of blue (France) in the bottom third of the plot.

9M 2019 Stock Perf. (%) - n=152

Waterfall Plot - 9M 2019 Stock Perf. (%) - n=152

Q3 2019 Highlights/Impact Events:
Gainers: Silence Therapeutics signed a deal with Mallinckrodt, Okyo disclosed a preclinical proof-of-concept in dry ARMD, Oasmia changed the management who makes peace with the main shareholder, phase 1a passed for Cyxone's T20K, Amryt resumed trading after a suspension due to the merger with Aegerion.
Decliners: Mologen's phase 3 of lefitolimod failed in maintenance treatment of CRC, Biophytis stock fall continued, no more hope for Motif Bio's iclaprim on the short term, FDA said no to Pharnext for a filing of PXT3003 (new trial required), IRLAB IRL790 phase 2a failed in PD-LID, mixed PK data for Gabather's GT-002 FIH trial, Alligator regained rights of ADC-1013 from Janssen.

European Biotech Q3 Perf. (%) - n=149/Nuevolution de-listed